Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 29Triple Negative Breast Neoplasms 10Neoplasm Metastasis 6Sarcoma 5Liposarcoma 3Inflammatory Breast Neoplasms 3Urinary Bladder Neoplasms 2Leiomyosarcoma 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Refractory Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Metastatic HER2-positive Breast Cancer 1Melanoma 1Lung Neoplasms 1Ketosis 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1HER2-negative Metastatic Breast Cancer 1HER2-low Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 49fludarabine 36Dexamethasone 35venetoclax 29pembrolizumab 26Rituximab 21Lenalidomide 18pomalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 11carfilzomib 11Temozolomide 11Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Injections 9Azacitidine 9selinexor 8Vincristine 8Carboplatin 8Bortezomib 8obinutuzumab 7Immunotherapy, Adoptive 7Bevacizumab 7zanubrutinib 6ruxolitinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × eribulin × 1 year × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡